Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 25, 2015 4:07 AM ET


Company Overview of Selecta Biosciences, Inc.

Company Overview

Selecta Biosciences, Inc. is a clinical-stage biotechnology company that develops targeted immunotherapies and vaccines that regulate immune responses to prevent and treat diseases. The company provides synthetic vaccine particles (SVP) therapies that are applied in various therapeutic areas with a focus on the inhibition of immunogenicity for protein therapies, treatment of allergies, and treatment of autoimmune diseases. Its SVP therapies prevent effects of anti-drug antibodies caused by the immunogenicity of biologic drugs in patients. The company develops antigen-specific tolerogenic SVPs to prevent and suppress pro-inflammatory responses against a specific antigen for the inhibition of ...

480 Arsenal Street

Building One

Watertown, MA 02472

United States

Founded in 2007





Key Executives for Selecta Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 61
Founder, Vice Chairman and Member of The Scientific Advisory Board
Age: 45
Co-Founder and Co-Chair of the Scientific Advisory Board
Co-Founder, Co-Chair of the Scientific Advisory Board and Director
Age: 66
Vice President of Finance
Compensation as of Fiscal Year 2014.

Selecta Biosciences, Inc. Key Developments

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

Selecta Biosciences, Inc. announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. In celiac disease patients, the consumption of gluten-containing food induces harmful immune responses that can lead to abdominal pain and, in most severe cases, intestinal cancer. This new immune tolerance program expands activities within the Sanofi-Selecta collaboration, which is already successfully advancing a novel immunotherapy for a life-threatening food allergy. The products resulting from this collaboration will leverage Selecta’s proprietary Synthetic Vaccine Particle (SVP™) platform, which has unique capabilities to engineer nanoparticles with the structure and composition to produce immune tolerance by attenuating the overactive response to specific antigens. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi.

Selecta Biosciences, Inc., JDRF and Sanofi Extends Collaboration to Develop Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta Biosciences, Inc., and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. This collaborative research program is aimed at accelerating the advancement of an SVP immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas. Selectas proprietary tolerogenic SVP products show potential to re-educate the immune system to stop or suppress pro-inflammatory responses against a specific antigen, thereby halting the undesirable immune reaction without causing harmful global immune suppression common with general immune system modulating drugs. As part of their collaboration, JDRF and Sanofi are co-financing the program with the aim of advancing the SVP product candidate to the clinic. This next phase of the SVP development program has been structured as a grant award to Selecta in order to test up to four antigens that may succeed in stopping the autoimmune response that destroys beta cells. JDRF has a strategic research plan designed to deliver a sustained stream of new, life-changing therapies.

Selecta Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 11:40 AM

Selecta Biosciences, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 11:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Werner Cautreels, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Genovics United States
Stryker Biotech LLC United States
Kalion, Inc. United States
Transcription Factor Therapeutics, Inc. United States
NephRx Corporation United States

Recent Private Companies Transactions

Private Placement
April 10, 2015
Private Placement
September 30, 2014
Private Placement
August 14, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Selecta Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at